SCHEMBL61085

SCHEMBL61085

C1=CC2C=CNC2C=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14135002 1.00
SCHEMBL9272391 0.88
SCHEMBL14678811 0.71
SCHEMBL12650515 0.64
SCHEMBL9715235 0.60
SCHEMBL3767412 0.60
SCHEMBL16361058 0.60
SCHEMBL14138851 0.58
SCHEMBL2437075 0.58
SCHEMBL1490201 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3961737-B1 COMPOSITION FOR PHOTOELECTRIC DEVICE, AND IMAGE SENSOR AND ELECTRONIC DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO LTD (KR) 2023-10-11 EP disclosed
US-11660289-B2 Deuterated or partially deuterated N,N-dimethyltryptamine compounds SMALL PHARMA LTD. (GB) 2023-05-30 US disclosed
US-11660289-B2 Deuterated or partially deuterated N,N-dimethyltryptamine compounds SMALL PHARMA LTD. (GB) 2023-05-30 US disclosed
US-20230131966-A1 FUNGICIDAL AMIDES FMC CORPORATION 2023-04-27 US disclosed
US-20230054458-A1 ANTI-CLAUDIN ANTIBODY-DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2023-02-23 US disclosed
US-11566003-B2 Isoquinolines as inhibitors of HPK1 GENENTECH, INC. (US) 2023-01-31 US disclosed
US-20220202775-A1 DEUTERATED OR PARTIALLY DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS SMALL PHARMA LTD (GB) 2022-06-30 US disclosed
US-20210163417-A1 ISOQUINOLINES AS INHIBITORS OF HPK1 GENENTECH, INC. (US) 2021-06-03 US disclosed
US-10844074-B2 Heterocycle compounds and uses thereof Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. (CN) 2020-11-24 US disclosed
US-10577362-B2 Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases GENOSCIENCE PHARMA (FR) 2020-03-03 US disclosed
WO-2009079767-A1 INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-07-02 WO disclosed
WO-2009015485-A1 CYCLIC INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2009-02-05 WO disclosed
WO-2008150486-A2 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS GENZYME CORPORATION (US) 2008-12-11 WO disclosed
US-20080234334-A1 1,4 DIAMINO BICYCLIC RETIGABINE ANALOGUES AS POTASSIUM CHANNEL MODULATORS VALEANT PHARMACEUTICALS INTERNATIONAL (US) 2008-09-25 US disclosed
WO-2008109991-A1 INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER UNIVERSITY HEALTH NETWORK (CA) 2008-09-18 WO disclosed
WO-2003011115-A2 PEPTIDE-BASED MULTIMERIC TARGETED CONTRAST AGENTS EPIX MEDICAL, INC. (US) 2003-02-13 WO disclosed
JP-2001220379-A METHOD FOR PRODUCING 3a,7a-DIHYDROINDOLE COMPLEX SUMITOMO CHEM CO LTD 2001-08-14 JP disclosed
EP-0327426-B1 Indolo[3,2,1-de][1,4]-oxazino[2,3,4-ij][1,5]naphthyridine derivatives, process for their preparation and intermediates, their use as medicaments and compositions containing them ROUSSEL UCLAF (FR) 1993-11-03 EP disclosed
US-4904655-A Novel indolo [3,2,1-de] [1,4] oxazino [2,3,4-ij] [1,5] ROUSSEL UCLAF (FR) 1990-02-27 US disclosed
EP-0327426-A1 Indolo[3,2,1-de][1,4]-oxazino[2,3,4-ij][1,5]naphthyridine derivatives, process for their preparation and intermediates, their use as medicaments and compositions containing them ROUSSEL-UCLAF (FR) 1989-08-09 EP disclosed